NVAX
Company Description
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.12B | 682.16M | 556.38M | 1.60B | 197.58M | 22.39M | 18.66M | 34.29M | 31.18M | 15.35M | 36.25M | 30.66M |
| Net Income | 440.30M | (187.50M) | (545.06M) | (657.94M) | (1.74B) | (418.26M) | (130.10M) | (184.75M) | (183.77M) | (279.97M) | (156.94M) | (82.95M) |
| EPS | 2.72 | -1.23 | -5.41 | -8.42 | -23.44 | -7.43 | -5.40 | -9.99 | -12.56 | -20.68 | -11.97 | -7.35 |
| Free Cash Flow | (250.19M) | (100.32M) | (772.77M) | (508.92M) | 265.46M | (97.16M) | (138.48M) | (186.20M) | (142.88M) | (273.68M) | (144.38M) | (74.28M) |
| FCF / Share | -1.54 | -0.66 | -7.67 | -6.51 | 3.57 | -1.69 | -5.75 | -10.07 | -9.76 | -20.21 | -11.01 | -6.58 |
| Operating CF | (244.63M) | (87.26M) | (713.97M) | (415.94M) | 322.95M | (42.54M) | (136.62M) | (184.82M) | (138.70M) | (255.47M) | (126.09M) | (67.01M) |
| Total Assets | 1.18B | 1.56B | 1.80B | 2.26B | 2.58B | 1.58B | 172.96M | 207.98M | 302.49M | 394.30M | 386.04M | 276.00M |
| Total Debt | 248.81M | 230.42M | 229.08M | 549.78M | 453.99M | 467.98M | 321.87M | 319.19M | 317.76M | 316.34M | 395,000 | 998,000 |
| Cash & Equiv | 240.63M | 530.23M | 568.50M | 1.34B | 1.52B | 553.40M | 78.82M | 70.15M | 106.31M | 144.35M | 93.11M | 32.34M |
| Book Value | (127.75M) | (623.84M) | (716.93M) | (634.08M) | (351.67M) | 627.21M | (186.02M) | (167.94M) | (101.73M) | (5.55M) | 292.67M | 229.62M |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -0.67 | N/A | N/A | N/A | N/A | -0.54 | -0.36 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 56.70M | 139.51M | 147.14M | 70.44M | 239.24M | 666.65M | 88.31M | 84.51M | 415.48M | 93.86M | 291.34M | 22.06M |
| Net Income | (53.39M) | (9.49M) | 17.53M | (202.38M) | 106.51M | 518.65M | (81.03M) | (121.30M) | 162.38M | (147.55M) | (178.39M) | (130.78M) |
| EPS | -0.32 | -0.06 | 0.11 | -1.25 | 0.66 | 3.22 | -0.51 | -0.76 | 1.11 | -1.05 | -1.44 | -1.26 |
| Free Cash Flow | (74.14M) | (33.69M) | (41.55M) | 105.79M | (127.71M) | (187.10M) | (175.41M) | (146.83M) | 311.14M | (90.81M) | (185.86M) | (58.05M) |
| FCF / Share | -0.45 | -0.21 | -0.26 | 0.65 | -0.79 | -1.16 | -1.09 | -0.92 | 2.10 | -0.65 | -1.50 | -0.56 |
| Operating CF | (75.41M) | (32.42M) | (39.48M) | 107.80M | (127.46M) | (185.50M) | (173.16M) | (144.81M) | 314.27M | (83.56M) | (176.78M) | (39.66M) |
| Total Assets | 955.58M | 1.04B | 1.18B | 1.18B | 1.34B | 1.29B | 1.56B | 1.71B | 1.82B | 1.35B | 1.80B | 1.66B |
| Total Debt | 295.60M | 295.06M | 248.81M | 251.14M | 228.49M | 228.66M | 230.42M | 233.31M | 233.25M | 229.33M | 229.08M | 222.11M |
| Cash & Equiv | 191.46M | 228.36M | 240.63M | 268.02M | 253.74M | 263.34M | 530.23M | 573.63M | 680.16M | 480.59M | 568.50M | 651.10M |
| Book Value | (190.71M) | (144.76M) | (127.75M) | (156.67M) | 37.62M | (75.64M) | (623.84M) | (526.44M) | (431.71M) | (867.08M) | (716.93M) | (678.35M) |
| Return on Equity | N/A | N/A | N/A | N/A | 2.83 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
